Drug Topics

AUGUST 22, 2024

Novavax is still awaiting FDA authorization for their protein-based COVID-19 vaccine.

Vaccines 387

Vaccines FDA 387

Drug Topics

OCTOBER 18, 2024

Vaccination against HPV can prevent thousands of cases of cancer each year.

Vaccines 307

Vaccines 307

Drug Topics

OCTOBER 25, 2024

Analyzing outcomes from the COVID-19, influenza, and pneumococcal vaccines, researchers explored the effectiveness and patient hesitancy surrounding each vaccine.

Vaccines 247

Vaccines 247

Drug Topics

MAY 21, 2024

Research presented at DDW 2024 found there was no significant association between immune response and hepatitis B vaccine types in patients with Hepatitis C.

Immunization 281

Immunization Vaccines 281

Drug Topics

OCTOBER 17, 2024

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

Vaccines 247

Vaccines FDA 247

Drug Topics

OCTOBER 26, 2024

David Ha, PharmD, BCIDP, discusses why pharmacies should begin offering more vaccines and how they can better market their services to the community.

Independent Pharmacies 247

Independent Pharmacies Vaccines 247

Drug Topics

JUNE 20, 2024

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

Vaccines 216

Vaccines 216

Drug Topics

JUNE 7, 2024

Vaccinated men and women are at a reduced risk for HPV-related cancers, according to research presented at ASCO 2024.

Vaccines 216

Vaccines 216

Pharmaceutical Technology

JUNE 13, 2025

June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.

Vaccines 87

Vaccines Communication Hospitals Packaging 87

Pharmacy Times

OCTOBER 20, 2023

An overview of updated CDC ACIP recommendations for COVID-19 vaccines available through commercial channels for the 2023-2024 season.

Vaccines 123

Vaccines 123

Pharmacy Times

SEPTEMBER 13, 2023

The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.

Vaccines 139

Vaccines Immunization 139

Pharmacy Times

OCTOBER 26, 2024

With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.

Vaccines 132

Vaccines 132

Pharmaceutical Technology

SEPTEMBER 13, 2024

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination campaign.

Vaccines 143

Vaccines 143

Pharmacy Times

JUNE 20, 2025

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period. 1,2 A particular disease burden is present for Black Americans.

Vaccines 73

Vaccines Compounding Pharmacies Immunization Hospitals 73

Pharmacy Times

SEPTEMBER 25, 2023

For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.

Vaccines 148

Vaccines Immunization 148

Pharmacy Times

OCTOBER 4, 2024

Significant polarization surrounding COVID-19 vaccinations in late 2020 and early 2021 looked to have had an impact in increasing vaccine hesitancy.

Vaccines 132

Vaccines 132

Pharmacy Times

JANUARY 22, 2024

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

Vaccines 127

Vaccines Immunization 127

STAT

OCTOBER 5, 2023

The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as possible, pressing the FDA and manufacturers to try to get the work done on an expedited timeline. Read the rest…

Vaccines 143

Vaccines FDA 143

Pharmacy Times

OCTOBER 3, 2023

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

Vaccines 145

Vaccines FDA 145

Pharmaceutical Technology

MAY 9, 2025

Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from Q1 2024.

Vaccines 52

Vaccines 52

STAT

MARCH 5, 2024

When Americans line up for flu vaccines next fall, they will almost certainly be getting vaccines that no longer contain protection against a family of flu viruses that appears to be extinct.

Vaccines 124

Vaccines FDA 124

Pharmacy Times

JANUARY 27, 2025

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Vaccines 82

Vaccines 82

Pharmaceutical Technology

OCTOBER 13, 2023

The Phase IIb SurVaxM vaccine study will enrol 265 patients and has an estimated completion date in Q2 2024.

Vaccines 111

Vaccines FDA 111

Fierce Pharma

MAY 6, 2024

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.

Vaccines 133

Vaccines 133

Pharmacy Times

SEPTEMBER 2, 2024

Robert Walker discusses the updated COVID-19 vaccines targeting the new JN.1 1 lineage of the virus and the challenges of addressing vaccine hesitancy to protect individuals and communities.

Vaccines 90

Vaccines 90

Pharmacy Times

JULY 23, 2024

With new guidance coming for the 2024-2025 season, pharmacists must stay up to date with current vaccine recommendations.

Vaccines 94

Vaccines 94

Pharmaceutical Technology

SEPTEMBER 12, 2023

adapted monovalent Covid-19 vaccine, COMIRNATY 2023-2024 Formulation. The US FDA has approved Pfizer and BioNTech’s sBLA for Omicron XBB.1.5-adapted

Vaccines 111

Vaccines FDA 111

Fierce Pharma

JANUARY 30, 2024

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. kdunleavy Tue, 01/30/2024 - 08:58 How will it fare in latest round of GSK showdown?

Vaccines 125

Vaccines 125

Fierce Pharma

OCTOBER 24, 2023

On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. | On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year.

Vaccines 113

Vaccines FDA 113

Fierce Pharma

JULY 31, 2024

The whole respiratory syncytial virus (RSV) vaccine field took a beating when the Centers for Disease Control and Prevention’s (CDC's) immunization committee doled out a limited recommendation last | The whole RSV vaccine field took a beating when the CDC’s immunization committee doled out a limited recommendation last month.

Vaccines 104

Vaccines Immunization 104

Pharmaceutical Technology

JUNE 20, 2025

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.

Vaccines 52

Vaccines Communication Hospitals Packaging 52

Fierce Pharma

MAY 2, 2024

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday.

Vaccines 109

Vaccines Immunization 109

Fierce Pharma

APRIL 26, 2024

GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots fkansteiner Fri, 04/26/2024 - 10:07

Vaccines 105

Vaccines 105

Hospital Pharmacy Europe

JUNE 23, 2023

The UK should introduce routine vaccination for respiratory syncytial virus (RSV) to protect babies and older adults, the Joint Committee on Vaccination and Immunisation (JCVI) has recommended. The post JCVI backs RSV routine vaccination for babies and older adults in the UK appeared first on Hospital Pharmacy Europe.

Vaccines 98

Vaccines Hospitals 98

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . of individuals in low-income countries have received their first dose.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Vaccines 98

Vaccines 98

Pharmacy Times

DECEMBER 13, 2024

Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.

Vaccines 65

Vaccines 65